Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA.

@article{Kbler2011FinalAO,
  title={Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA.},
  author={Hubert K{\"u}bler and Tobias Maurer and Arnulf Stenzl and Susan Feyerabend and Ursula Steiner and Martin Schostak and Wolfgang Schultze-Seemann and Frank vom Dorp and Lorenzo Pilla and G Viatali and Christian Hampel and Susanne Wedel and Lutz Trojan and Kristina Hiller and M. Sommerauer and Dieter Jocham and Birgit Scheel and Thomas Lander and K Kallen and Kurt Miller},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={4535}
}
4535 Background: CV9103 is a prostate cancer (PCA) vaccine that contains the four antigens PSA (prostate specific antigen), PSCA, PSMA and STEAP1 as self-adjuvanted full-length mRNAs. METHODS Patients with castrate resistant PCA with rising PSA and predominantly existing metastases (> 80%) were enrolled into a first-in-man phase I/IIa study. The primary endpoint was safety, the secondary immunogenicity. Three different dose levels (256µg, 640µg and 1280µg total mRNA) were tested in the phase… CONTINUE READING